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ABSTRACT
Introduction Edinburgh and Lothians’ Viral Intervention 
Study Kids is a parallel, open- label, randomised controlled 
trial of hypertonic saline (HS) nose drops (~2.6% sodium 
chloride) vs standard care in children <7 years of age with 
symptoms of an upper respiratory tract infection (URTI).
Methods and analysis Children are recruited prior to 
URTI or within 48 hours of developing URTI symptoms by 
advertising in areas such as local schools/nurseries, health 
centres/hospitals, recreational facilities, public events, 
workplaces, local/social media. Willing parents/guardians, 
of children <7 years of age will be asked to contact 
the research team at their local site. Children will be 
randomised to either a control arm (standard symptomatic 
care), or intervention arm (three drops/nostril of HS, at 
least four times a day, until 24 hours after asymptomatic or 
a maximum of 28 days). All participants are requested to 
provide a nasal swab at the start of the study (intervention 
arm: before HS drops) and then daily for four more days. 
Parent/guardian complete a validated daily diary, an end 
of illness diary, a satisfaction questionnaire and a wheeze 
questionnaire (day 28). The parent/guardian of a child in 
the intervention arm is taught to prepare HS nose drops. 
Parent/guardian of children asymptomatic at recruitment 
are requested to inform the research team within 48 
hours of their child developing an URTI and follow the 
instructions already provided. The day 28 questionnaire 
determines if the child experienced a wheeze following 
illness. Participation in the study ends on day 28.
Ethics and dissemination The study has been 
approved by the West of Scotland Research Ethics 
Service (18/WS/0080). It is cosponsored by Academic 
and Clinical Central Office for Research and 
Development—a partnership between the University of 
Edinburgh and National Health Service Lothian Health 
Board. The findings will be disseminated through peer- 
reviewed publications, conference presentations and via 
the study website.
Trial registration number NCT03463694.
INTRODUCTION
Viral upper respiratory tract infections 
(URTIs) are very common in childhood 
resulting in a significant burden on the popu-
lation and health services.1 The annual inci-
dence rate of URTI in childhood can vary 
between 6 and 12 episodes.2 3 Children have 
a longer duration of illness (mean 1.8 weeks; 
SD: 1.3 weeks) compared with adults.3 4 In 
Scotland, URTI is the leading cause of general 
practitioner (GP) visits in children <5 years 
(n=84 710, 574/1000 population) and the 
fourth most common cause of consultation 
in children aged 5–14 (n=33 790, 116.5/1000 
population).5 In secondary care, in 2015–
16, 13.3% (n=16 644) and 19.7% (14 600) 
of all admissions/emergency admissions 
respectively in children were due to URTI/
lower respiratory tract infections.6 A total of 
12%–14% of children who develop an URTI 
will go on to develop lower respiratory tract 
disease (viral induced wheeze: 80/1000,7 
Strengths and limitations of this study
 ► Open- label community- based randomised con-
trolled study investigating the effectiveness of hy-
pertonic saline (HS) versus standard treatment in 
children under 7 years of age with a common cold.
 ► Parents in the intervention arm are taught to safely 
make HS at home.
 ► Nose swabs are collected to identify the virus(es) 
and to measure change in viral shedding.
 ► A validated symptom score diary (Canadian Acute 
Respiratory Illness and Flu Scale) is used as part of 
the daily diary.
 ► There is no placebo arm.
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bronchiolitis: 46/10008 and pneumonia: 0.27 episodes/
child year.9 Hence interventions that reduce URTI severity 
may considerably benefit patients/carers and reduce 
pressure on the National Health Service (NHS). Since 
>200 viruses10 can cause an URTI, individually targeted 
antiviral therapy is impractical and measures that work 
against all viruses are required.
New data suggest that hypertonic saline (HS) may be 
able to suppress viral replication, regardless of viral type 
and hence be a potential respiratory antiviral agent with 
clinical application. Saline irrigation is commonly used 
in clinical practice, mostly to deliver a mucolytic effect. 
However, we have recently identified that human epithe-
lial (cervical- HeLa, respiratory- A549) cells use sodium 
chloride (NaCl) to mount a broad- spectrum antiviral 
effect against representative DNA, RNA enveloped and 
non- enveloped viruses.11 The antiviral effect is dependent 
on the entry of chloride ions into the cell and the produc-
tion of intracellular hypochlorous acid (HOCl).11 HOCl is 
the active ingredient of bleach, which can inactivate most 
viruses.12–15 A polymorphism causing reduction in HOCl 
production has been reported in individuals with cervical 
cancer.16 Since cervical cancer follows infection with high- 
risk types of human papilloma viruses, it suggests a key 
role for local antiviral mechanisms. HOCl production is 
an important antibacterial mechanism in human neutro-
phils.17 Increased HOCl production is reported within 
gut epithelial cell of fruit flies after bacterial lysate inges-
tion.18 These data suggest an anti- infective role of HOCl 
and its precursor NaCl in epithelial cells.
In addition, it has recently been shown that accumu-
lation of Na+ ions in human skin helps fight bacterial/
parasitic infections.19 20 A high salt diet increased Na+ 
in skin leading to a hypertonic environment, increased 
nitric oxide (NO) production in macrophages and 
thereby pathogen removal.19 20 While our laboratory data 
point to the importance of Cl− in combating viral infec-
tions, Jantsch et al have shown the importance of Na+ in 
fighting bacterial infections. Taken together, these data 
suggest that innate immunity may be dependent on NaCl 
in epithelial cells helping to clear bacterial and viral 
infection.
Nebulised HS has been used to treat bronchiolitis; 
an acute viral infection of young children caused by a 
variety of respiratory viruses. Meta- analyses of current 
trials suggest a possible reduction in length of hospital 
stay,21 22 but the association is weak and there have been 
concerns about the replicability of this finding23–27 poten-
tially as HS has been given at the peak of disease when 
viral load is maximum and lower respiratory tract disease 
(with potential dysregulated immune response) is estab-
lished. More positive signals have been demonstrated 
when HS has been administered in accident and emer-
gency department contexts to reduce hospital admission 
rates: data remain conflicting and a systematic review has 
been started to analyse data as they emerge.26–28
The role of saline (isotonic or hypertonic) in children 
with viral URTI has been explored in two published 
studies. In children aged 6–10 years administered isotonic 
saline as a spray (six times/day), there was a significant 
reduction in reported sore throat, nasal secretions and 
use of nasal decongestants/mucolytic (vs standard care, 
no placebo).29 In children <2 years treated with saline/
sea water drops (three times a day for 5 days), there 
was a significant reduction in URTI symptoms reported 
when compared with untreated children.30 However, a 
Cochrane review concluded that no definitive conclusions 
could be drawn as the available studies were small and 
had major methodological limitations: baseline symptom 
score was calculated over 7 days (not at the point of entry) 
and groups had different characteristics at baseline.31
We recently completed the Edinburgh and Lothians’ 
Viral Intervention Study (ELVIS), an open label pilot 
randomised controlled trial (RCT) of HS nasal irrigation 
and gargling (HSNIG) in 66 adults with an URTI ( www. 
elvisstudy. com).4 Most participants were infected with 
rhinoviruses/coronaviruses. The intervention arm had 
a 22% reduction in duration of illness (mean (SD) of 
intervention arm: 6.8 days (2.2) and control arm 8.7 days 
(3.3), difference of 1.9 days; p=0.01). Ninety- three per 
cent believed HSNIG helped improve symptoms of the 
cold. There was 36% reduction in over- the- counter medi-
cation use (p=0.003), transmission within household was 
reduced by 35% (p=0.006) and viral shedding reduced at 
a faster rate of ≥0.5 log10/day in those receiving HSNIG 
(p=0.04).4 The reduction in viral shedding and transmis-
sion within household were supportive of our laboratory 
data and consistent with a direct cellular antiviral action 
by NaCl.
Given the laboratory evidence, supported by our 
demonstration of clinical benefits in adults, an RCT in 
children with URTI to study the effects of HS on duration 
of illness and viral shedding is now needed. No suitable 
placebo is available: Sodium bicarbonate and plain water 
cause discomfort when administered to nasal mucosa and 
normal saline, a commonly used, safe, placebo contains 
NaCl and so may not act as a placebo. For these reasons, 




To investigate whether the use of parent/guardian- 
initiated HS nose drops administered to children with 
symptoms consistent with acute viral URTI reduces the 
duration of symptoms when compared with children 
managed using standard care.
Secondary objectives
To determine the effect of HS nose drops on:
1. Severity of all symptoms.
2. Duration and severity of individual symptoms.
3. Contact with NHS 24, out of hours primary care 
(OOH), and primary care (GP).
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4. Hospital attendance (ie, A&E attendance and/or 
hospital admission) and diagnosis.
5. Reduction in wheeze.
6. Over the counter medication use.
7. Duration, reduction or rate of reduction in viral 
shedding.
8. Transmission within the household.
9. Side effects associated with the use of saline nose 
drops.
10. Adverse events (AEs) associated with the use of saline 
nose drops.
11. Time off from school/nursery for child and workdays 
lost for parent/guardian.
12. Cost associated with illness (over the counter medica-
tion costs and NHS costs).
Study design and sample size
ELVIS Kids is a parallel, open label, RCT of HS nose drops 
(~2.6% NaCl) versus standard care in children <7 years of 
age with symptoms of an URTI. The aim is to recruit a 
total of 480 children (240/arm).
The study will run over ~42 months at participating 
sites in Scotland (sites are as listed on  ClinicalTrials. 
gov). Children are recruited prior to, or within 48 hours 
of developing URTI symptoms by advertising in areas 
such as local schools, nurseries, health centres, hospi-
tals, recreational facilities,workplaces public events and 
the community as well as local and social media. For the 
purposes of this study an URTI is defined as: at least two 
respiratory symptoms (nasal congestion, runny nose, 
cough, sore throat) or one respiratory symptoms and at 
least one systemic symptom (low energy/tired, muscle 
aches/pains, headache, fever ≥38°C). Willing parents/
guardians, will be directed by the study advertising to 
contact the research team at their local site) if they are 
interested in participating.
Children will be randomised to either a control arm 
of standard symptomatic care, or an intervention arm of 
three drops each nostril of HS at least four times a day 
and up to a maximum of 12 times a day until asymptom-
atic or maximum of 28 days. All parents/guardians will be 
requested to obtain a mid- turbinate nasal swab from the 
participant first thing in the morning (before nose drops 
in the intervention arm) for five consecutive days (unless 
the child is well before then), a daily diary (a global 
severity question, Canadian Acute Respiratory Illness and 
Flu Scale (CARIFS),32 a validated illness measure in the 
UK, side effects and compliance with trial procedures) 
until they report the child as ‘not unwell’, an end of illness 
diary (infection in household contacts, ease of use and 
acceptability of intervention, medication and healthcare 
use, acceptability, time taken off usual activities, wheezing 
and whistling in the chest), a satisfaction questionnaire 
and AEs. Parents/guardians of the children allocated to 
the intervention arm will be taught how to prepare the HS 
(including sterilisation instructions for children under a 
year). Parents/guardians of children who are asymptom-
atic at recruitment are requested to inform their local 
research team when the child develops an URTI (within 
48 hours) and follow the instructions already provided to 
them. On day 28, parents/guardians will be contacted to 
determine if their child suffered from wheezing or whis-
tling in the chest either during the illness or at any point 
until day 28. Participation in the study will end on day 28.
Eligibility and consent
Prescreening for eligibility to participate will be completed 
by a member of the research team at the clinical trials 
unit when parents/guardians phone to express interest 
in the study. If parents/guardians attend an appoint-
ment and take part in the study, the study number will 
be recorded on the screening log and details of eligibility 
will be recorded in the study database.
Inclusion criteria
1. Children between corrected gestational age of ≥40 
weeks and <7 years of age.
2. Children without URTI OR ≤48 hours of URTI* 
starting.
*An URTI being defined as at least two respiratory 
symptoms (nasal congestion (ie, stuffy nose), runny nose, 
cough, sore throat) or one respiratory symptom+at least 
one systemic symptom (low energy/tired, muscle aches/
pains, headache, fever 38°C).
Exclusion criteria
1. Children needing immediate medical attention.
2. Children using saline drops/sprays at the time of 
randomisation.
3. Children on immunosuppressive medication, regular 
oral/inhaled steroids, regular antibiotics (use of an-
tibiotics is allowed as long as the child does not need 
regular antibiotics).
4. Children with a known chronic illness (eg, cystic fi-
brosis, cardiac, renal, liver, lung, neurological con-
ditions) apart from wheeze or asthma which are not 
exclusions if the child is otherwise well and not on 
regular steroids).
5. Children being followed up for developmental delay.
6. Children receiving the nasal influenza vaccine ≤14 
days ago.
7. Children taking part in another interventional trial.
8. If parents/guardians indicating that they are un-
able to comply with the study protocol prior to 
randomisation.
9. If parents/guardians are unable to understand writ-
ten or spoken English.
10. Children randomised to ELVIS KIDS on a previous 
episode of URTI.
11. Children with a concurrently participating sibling.
All ineligible and non- recruited participants will be 
recorded on the ELVIS Kids screening log with a reason 
given.
Obtaining consent
Only trained and delegated members of the trial team 
will take consent—this will usually be the research nurse. 
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The participant information sheet (PIS), which will 
explain the aims of the study and the potential risks and 
benefits of the study treatment, are provided to parents/
guardians when they meet the research team (also avail-
able online). A children’s PIS will be available to discuss 
with older children attending the appointment with the 
option of giving their assent (online supplemental file 1).
If the parent/guardian wishes to participate in the study, 
then they will be asked to sign the informed consent form 
(ICF) (online supplemental file 1). Both the parent/
guardian and the person delegated to take consent will 
sign and personally date the ICF. The original signed ICF 
must be kept by the Investigator in the investigator site 
file, one copy is provided to the parent/guardian, one 
copy is placed in TRAK. The same would apply in the case 
of assent being given.
Randomisation and treatment allocation
A member of the research team from the clinical research 
facility will perform the randomisation using a web- based 
randomisation service managed by the Edinburgh Clin-
ical Trials Unit (ECTU). Children will be allocated to 
receive either HS nose drops or standard care in a 1:1 
ratio using minimisation based on age (0–2, >2 years) and 
sex and allocated to receive the treatment which mini-
mises the imbalance with a probability 0.8. The study is 
not blinded apart from those carrying out lab assessments 
of nasal swabs.
Sea salt will be provided by Cornish Sea Salt company 
in 225 g pots. They will be supplied to local pharmacies 
where they will be labelled and stored. A working stock 
will be issued to the research team. If a child is allocated 
to an intervention arm, the parent/guardian will be given 
instructions on the preparation and use of HS nose drops 
using instructional video, verbal and written information. 
Parents/guardians will be asked to add one level measure 
of sea salt to a fixed volume of freshly boiled water using 
the measuring spoon and clean glass jar provided. This 
provides a NaCl concentration of ~2.6% and the drops 
can be used once cooled. Two glass jars are provided 
so that the parent/guardian could use one and have a 
clean spare to prepare solution the next day. Two dropper 
bottles are provided with which nose drops can be applied 
(one in use, and a clean spare).
Withdrawal of study participants
Parents/guardians are free to withdraw their child from 
the study at any point. If withdrawal occurs, the primary 
reason for withdrawal will be documented in the partici-
pant’s case report form (CRF), if given. All data and swabs 
collected before withdrawal will be retained for analysis in 
cases where participants withdraw.
Study assessments
The protocol is designed in accordance with the Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT). The trial overview of the study 
assessments is available as a SPIRIT figure (table 1). At 
the appointment, a member of the research team will 
train the parent/guardian how to identify an URTI, how 
to measure temperature, how to complete the diaries 
and how to collect and return the mid- turbinate swabs. 
In addition, those in the intervention arm will be given 
instructions on how to prepare and apply nose drops. 
Baseline information on the child, contact details of 
parent/guardian and number of household members at 
the time of recruitment will be collected in the electronic 
CRF (eCRF). If recruited when symptomatic, parents will 
be instructed to start the study assessments the same day. If 
recruited when asymptomatic, and there are no changes 
to the child’s medical information, parent/guardians 
will be asked to start the study assessments and to inform 
the study team the same day if possible or at least within 
2 days of onset of illness. If recruited when asymptomatic, 
and there are changes to the child’s medical informa-
tion, parent/guardians will be asked to contact the study 
team to ensure the child still meets the eligibility criteria 
before starting the study procedures. If it is not suitable 
for the child to take part during this URTI (eg, received 
the influenza vaccine in the past 2 weeks) they will remain 
on study and be asked to contact the team at the onset of 
the next URTI.
Parents/guardians are requested to collect a nasal 
(mid- turbinate) swab as soon as possible on day 1 and first 
thing in the morning (and prior to HS nose drops being 
applied) on days 2–5 if children remain unwell. These 
samples are to be packed in the transport box provided, 
stored in the fridge and returned in the prepaid enve-
lope or as soon as possible after completing collection. 
If samples are not received by day 10, a reminder will be 
sent to the parent/guardian.
Parents/guardians will complete a daily diary (online 
supplemental file 1) which records any symptoms the 
child is experiencing, compliance to nasal swabs and HS 
drops, any side effects and use of healthcare services. 
Parents will be taught how to measure temperature 
with TempaDot. Parents are advised to measure the 
temperature only if they think the child has a fever. If 
the child has an axillary temperature of ≥38°C, it should 
be recorded as a fever in the daily diary. The diaries will 
be provided as an online form (unless parents cannot 
access this in which case a paper copy can be provided). 
If the online Daily Diary is not completed a reminder 
will be sent.
An end of Illness diary (online supplemental file 1) 
and satisfaction questionnaire (online supplemental 
file 1) will be completed by the parent/guardian once 
the child is asymptomatic for >24 hours or after a 
maximum of 28 days. On day 28, the parent/guardian 
will be contacted by email and sent a text message to ask 
if their child has experienced any wheeze since the end 
of illness diary was completed (online supplemental file 
1).
Participants will be sent a £30 voucher by email as 
compensation for any inconvenience once they have 
returned the study data.
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Analysis and storage of samples
Up to five nasal swabs will be collected and posted to the 
Department of Laboratory Medicine, Royal Infirmary 
of Edinburgh, 51 Little France Crescent, Edinburgh, 
EH16 4SA, where they will be stored and processed. Day 
1 samples will be analysed by the respiratory panel and 
the cycle threshold (CT) of positive samples recorded. If 
the day one sample is missing, the first available sample 
will be tested to identify the virus. If an agent is identi-
fied, all samples (days 1–5) will be tested in parallel to 
estimate change in viral shedding and the CT recorded. If 
a sample is positive on day 1 and negative on subsequent 
days, they may be tested for human DNA to confirm a 
sample was collected. Log conversion of each positive 
result will be done using the following formula: (40- CT 
of specimen)/3.3 to estimate change in shedding. All 
nucleic acid extracts and remaining original samples will 
be stored in the Lothian NHS research Scotland BioRe-
source biobank (REC reference 15/ES/0094) and can be 
used in future ethically approved studies.
Outcomes/endpoints
Primary endpoint
Duration of illness (measured as the number of days until 
the parent reports the child to be well).
Secondary endpoints
1. Severity of all symptoms as measured by CARIFS.
2. The length of time for individual symptoms to resolve.
3. Severity of individual symptoms.
4. Contacting healthcare (NHS 24, OOH, GP) (number 
of participants and frequency of contacts).
5. Participants needing GP appointments (number of 
participants and frequency of contacts).
6. Participants attending hospital and diagnosis (num-
ber of participants and frequency of contacts).
7. Length of stay in hospital if admitted.
8. Number of participants reporting wheeze during ill-
ness and between end of illness to 28 days.
9. Number of participants reporting over the counter 
medication use.
10. Duration of viral shedding.
11. Reduction in viral shedding.
12. Rate of reduction in viral shedding.
13. Reduction in transmission to household contacts.
14. Number of participants reporting side effects associ-
ated with nasal drops.
15. Number of participants reporting AEs associated with 
nasal drops.
16. Types and severity of side effects/AEs reported.
17. Number of days lost from school/nursery for child.
Table 1 Assessments and timepoints
Study timepoints
Prescreen 
ing Baseline Day 1 Day 2 Day 3 Day 4 Day 5 Days 5–8
Days 5–28 (as 
applicable) Day 28
Prescreening X                   
Informed consent   X                 
Eligibility criteria   X                 
Eligibility review if 
change in health 
information
    X               
Randomisation/
treatment allocation
  X                 
Baseline case 
report form
  X                 
Nose swab 
collection (if child 
remains unwell)
    X X X X X       
Nose swab return               X     
Intervention arm—
HS drops
    X X X X X   X   
Daily diary     X X X X X   X   
Adverse events     X X X X X   X   




Return of diaries                 X   
Day 28 wheeze 
question
                  X
HS, hypertonic saline.
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18. Number of days lost from work for parent/guardian.
19. Cost of over the counter medication used.
20. NHS costs associated with illness.
Participant timeline
The participant pathways can be seen in figures 1 and 2. 
Participants will be active in the study for 28 days. There 
are no long- term follow- up assessments after day 28 of 
URTI developing.
Data collection
Baseline data will be collected on the baseline eCRF by 
a member of the research team. Parents/guardians will 
record study data onto either an online form which will 
be saved into the eCRF. A paper CRF (pCRF) option is 
available if a parent/guardian prefers it. pCRF will be 
returned to the local research team and transcribed by a 
member of the research team into the database and cross- 
checked by another.
Virological results are downloaded (identifiable by 
study number) on a weekly basis on to a specific drive by 
the laboratory information management and technology 
team. These will be emailed to the ECTU on a monthly 
basis and uploaded into the study database.
The trial database will be created and maintained by 
ECTU. Trained and delegated members of the research 
team will be given password- protected logins to the data-
base to complete data entry. Data completed online by 
parents/guardians will be transmitted into the study 
database. The data will be stored in a secure server in 
the University of Edinburgh for at least the archiving 
period.
Figure 1 ELVIS Kids Patient Pathway when the child has 
an URTI at recruitment. ELVIS, Edinburgh and Lothians’ Viral 
Intervention Study; URTI, upper respiratory tract infection.
Figure 2 ELVIS Kids Patient Pathway when the child does 
not have an URTI at recruitment. ELVIS, Edinburgh and 
Lothians’ Viral Intervention Study; URTI, upper respiratory 
tract infection.
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Adverse events
Symptoms and side effects from the daily diary will be 
recorded in the CRF but will not be recorded as an AE or 
adverse reaction. Hospitalisation is a study outcome and 
is exempt from reporting to the sponsor as a serious AE.
Any other AEs identified between day 1 and 28 of the 
study will be recorded. Any events reaching seriousness 
criteria will be reported to the sponsor within 24 hours.
Sample size calculation and statistical analysis
Sample size calculation is based on mean (SD) dura-
tion of illness values in a control population from 
Gruber et al of 13 (9) days. To detect a 20% difference 
in mean duration, that is, 3 days, using a two sided, two- 
sample test with 5% level of significance, 90% power 
and common SD of 9 days we will need a sample of 191 
per treatment arm, without drop- outs. Hence, we will 
recruit 240 participants per arm to allow for up to 20% 
drop- outs.
Statistical analysis will be conducted according to the 
details specified in the prespecified statistical analysis 
plan. Differences in illness duration between treatment 
arms will be compared using a two- sample t- test or non- 
parametric equivalent, as appropriate. This method will 
also be employed to examine differences between treat-
ment arms for other continuous outcome measures such 
as average symptom score, viral shedding between treat-
ment arms. For binary categorical data, for example, the 
proportion of participants per arm attending their GP, 
attending hospital, etc, we will compare the treatment 
arms using a binomial test for the comparison of propor-
tions. Where we have categorical data with more than two 
categories a χ2 test will be used to examine the relation-
ships between treatment arms. If the number of cases of 
individual viruses are sufficient, the above analysis will be 
repeated by virus type.
Oversight arrangements
The study is cosponsored by Academic and Clinical 
Central Office for Research and Development, a part-
nership between the University of Edinburgh and NHS 
Lothian Health Board based at QMRI, 47 Little France 
Crescent, Edinburgh Email:  enquiries@ accord. scot. The 
trial will be coordinated by a Project Management Group, 
consisting of the chief investigator, coinvestigators, trial 
manager, statistician and coordinating nurse. The trial 
manager will oversee the study and will be accountable 
to the chief investigator. ECTU is responsible for trial 
management and oversight of data collection. The Edin-
burgh Clinical Research Facility are responsible for the 
statistical analysis. A Delegation Log will be prepared, 
detailing the responsibilities of each member of staff 
working on the trial. A trial steering committee (TSC) 
has been established to oversee the conduct progress. 
As there will be no data monitoring committee for this 
project, the TSC will review safety information as part of 
their remit.
Ethics and dissemination
The study will be conducted in accordance with the prin-
ciples of the International Conference on Harmonisation 
Tripartite Guideline for Good Clinical Practice (ICH). 
The study has been approved by the West of Scotland 
Research Ethics Service (reference: 18/WS/0080). Any 
changes in research activity, except those necessary to 
remove an apparent, immediate hazard to the participant 
in the case of an urgent safety measure, will be reviewed 
and approved by the chief investigator. Amendments will 
be submitted to the sponsor for review and authorisation 
before being submitted in writing to the appropriate REC, 
and local research and development office for approval 
prior to participants being enrolled into an amended 
protocol. The findings will be disseminated through peer- 
reviewed publications, conference presentations and on 
the study website.
Confidentiality
All laboratory specimens, evaluation forms, reports, and 
other records must be identified in a manner designed 
to maintain participant confidentiality. All records must 
be kept in a secure storage area with limited access. Clin-
ical information will not be released without the written 
permission of the participant’s parent/guardian. The 
Investigator and study site staff involved with this study 
may not disclose or use for any purpose other than perfor-
mance of the study, any data, record or other unpublished, 
confidential information disclosed to those individuals 
for the purpose of the study. Prior written agreement 
from the sponsor or its design must be obtained for the 
disclosure of any said confidential information to other 
parties.
All Investigators and study site staff involved with this 
study must comply with the requirements of general 
data protection regulations with regard to the collection, 
storage, processing and disclosure of personal informa-
tion and will uphold the Act’s core principles. Access to 
collated participant data will be restricted to individuals 
from the research team treating the participants, repre-
sentatives of the sponsor(s) and representatives of regu-
latory authorities. Computers used to collate the data will 
have limited access measures via user names and pass-
words. Published results will not contain any personal data 
that could allow identification of individual participants.
Patient and public involvement
Feedback was obtained from patient and public involve-
ment (PPI) representatives on the study protocol, infor-
mation sheets, diaries and consent forms and necessary 
modifications made prior to starting the study. A PPI 
representative is also invited to attend the trial steering 
committee meetings.
Access to data
Ownership of the data arising from this study resides with 
the study team. On completion of the study, the study data 
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will be analysed and tabulated, and a clinical study report 
will be prepared in accordance with ICH guidelines.
Trial status
This paper describes study protocol version V4 
(06/01/2020). The trial opened on 2 November 2018. 
The first participant was recruited on 6 November 2018. 
The planned study end date is 30 November 2021. At the 
time of submission, study recruitment was suspended due 
to the COVID-19 pandemic.
DISCUSSION
The study is based on the recently discovered evidence that 
epithelial cells have an innate antiviral effect.11 This effect 
can be augmented by supplying the cells with chloride 
ion through NaCl. Saline, commonly used as a placebo 
cannot be used in that role here as it contains NaCl—
the substrate being tested. We are hence measuring viral 
shedding as an independent measure of any antiviral 
effect. The results from this trial will help determine if 
a simple and low- cost intervention could help to reduce 
the duration of symptoms of URTI in children. Changes 
to the duration of individual symptoms, wheeze, trans-
mission within the household, over- the- counter medica-
tion use, need for further treatment, days lost and cost of 
illness are all secondary outcomes.
Conclusion
Since numerous viruses can cause URTI and in the 
absence of an antiviral agent/vaccine against the vast 
majority of viruses, if successful, this low cost and easily 
accessible intervention can easily be rolled out globally.
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